BioSpace News Archive

Biomerica, Inc. announced that the Canadian Patent Office has issued a notice of allowance for Biomerica’s patent application pertaining to the Company’s InFoods® diagnostic guided therapy platform technology that offers a novel approach in the treatment of patients suffering from Irritable Bowel Syndrome.

Bicycle Therapeutics plc, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, announced that the first patient has been dosed in the Phase I dose escalation portion of a company-sponsored Phase I/II trial of BT7480, a novel, fully synthetic Bicycle tumor-targeted immune cell agonist™ targeting Nectin-4 and agonizing CD137.

Madrigal Pharmaceuticals, Inc. provides a summary of corporate accomplishments and reports its third quarter 2021 financial results.

Leuven Belgium,4 November 2021: reMYND NV, a clinical stage company developing innovative treatments for Alzheimer’s, diabetes, epilepsy and other diseases caused by cellular dysfunction, announces the acceptance of ReS3-T, the Company’s lead epilepsy drug candidate, into the US NIH’s National Institute of Neurological Disorders and Stroke Epilepsy Therapy Screening Program.

ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, reported its financial and operating results for the third quarter ended September 30, 2021, and provided a business update.

Chimerix, a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, reported positive topline data from its 50-patient efficacy analysis of ONC201 for the treatment of recurrent H3 K27M-mutant glioma.

Chimerix, a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, reported financial results for the third quarter ended September 30, 2021 and provided an operational update.

Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems, announced that members of its senior management team are scheduled to participate in four upcoming investor conferences.

LAVA Therapeutics N.V., a clinical-stage biotechnology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, announced that Stephen Hurly, president and chief executive officer at LAVA, will participate in a virtual fireside chat for the 12th Annual Jefferies London Healthcare Conference taking place from Nov. 16-19, 2021.

TG Therapeutics, Inc. announced its financial results for the third quarter ended September 30, 2021 and recent company developments, along with a business outlook for the remainder of 2021.